In Ra'anana, Israel, on September 11, 2025, Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) revealed groundbreaking results for its HYLA blood sensor, attaining an impressive 97.35% accuracy in the recent performance trials, which will bolster its forthcoming submission to the U.S. Food and Drug Administration (“FDA”). This advancement marks a substantial improvement from the earlier findings released on March 4, 2025.